-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More

Sponsor: Takeda Pharmaceuticals
Program: Product Theaters
Monday, December 12, 2022: 8:00 AM-9:00 AM
Hall J - Theater 2 (Ernest N. Morial Convention Center)
Peter L. Turecek, Baxalta Innovations GmbH, part of Takeda
No relevant conflicts of interest to declare.
For in-person participants only
See more of: Product Theaters